JP2020537658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537658A5 JP2020537658A5 JP2020521539A JP2020521539A JP2020537658A5 JP 2020537658 A5 JP2020537658 A5 JP 2020537658A5 JP 2020521539 A JP2020521539 A JP 2020521539A JP 2020521539 A JP2020521539 A JP 2020521539A JP 2020537658 A5 JP2020537658 A5 JP 2020537658A5
- Authority
- JP
- Japan
- Prior art keywords
- condition
- general formula
- methyl
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 28
- -1 isotopic variants Chemical class 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 12
- 150000001450 anions Chemical class 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 208000023504 respiratory system disease Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 6
- 201000009267 bronchiectasis Diseases 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 229960002714 fluticasone Drugs 0.000 claims description 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960002657 orciprenaline Drugs 0.000 claims description 4
- 229960002052 salbutamol Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 2
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims description 2
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000004450 alkenylene group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003291 chlorphenamine Drugs 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229960001271 desloratadine Drugs 0.000 claims description 2
- 229960000533 dornase alfa Drugs 0.000 claims description 2
- 108010067396 dornase alfa Proteins 0.000 claims description 2
- 229960003592 fexofenadine Drugs 0.000 claims description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000676 flunisolide Drugs 0.000 claims description 2
- 229960000289 fluticasone propionate Drugs 0.000 claims description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 2
- 229960002848 formoterol Drugs 0.000 claims description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 239000000938 histamine H1 antagonist Substances 0.000 claims description 2
- 239000003396 histamine H4 receptor antagonist Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 229960001317 isoprenaline Drugs 0.000 claims description 2
- 229940039009 isoproterenol Drugs 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 229960005127 montelukast Drugs 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 229960005414 pirbuterol Drugs 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 229960004017 salmeterol Drugs 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 229960000195 terbutaline Drugs 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 229960004764 zafirlukast Drugs 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 description 9
- 230000007170 pathology Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1717051.5A GB201717051D0 (en) | 2017-10-17 | 2017-10-17 | Compounds |
| GB1717051.5 | 2017-10-17 | ||
| PCT/GB2018/052983 WO2019077340A1 (en) | 2017-10-17 | 2018-10-17 | BIS (PENTAHYDROXYHEXYL) AMINO-SUBSTITUTED 2 - {[(3-AMINO-PYRAZIN-2-YL) FORMAMIDO] METHYL} -1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATMENT OF RESPIRATORY DISEASES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537658A JP2020537658A (ja) | 2020-12-24 |
| JP2020537658A5 true JP2020537658A5 (enExample) | 2021-12-09 |
| JP7269923B2 JP7269923B2 (ja) | 2023-05-09 |
Family
ID=60419129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521539A Active JP7269923B2 (ja) | 2017-10-17 | 2018-10-17 | 呼吸器疾患治療のためのＥＮａＣ阻害剤としてのビス（ペンタヒドロキシヘキシル）アミノ置換された２－｛［（３－アミノ－ピラジン－２－イル）ホルムアミド］メチル｝－１Ｈ－１，３－ベンゾジアゾール－３－イウム誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11370778B2 (enExample) |
| EP (1) | EP3697788B1 (enExample) |
| JP (1) | JP7269923B2 (enExample) |
| GB (1) | GB201717051D0 (enExample) |
| WO (1) | WO2019077340A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201908453D0 (en) | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
| PE20221003A1 (es) | 2019-06-12 | 2022-06-15 | Tmem16A Ltd | Compuestos para tratar enfermedad respiratoria |
| JP2023552638A (ja) | 2020-12-11 | 2023-12-18 | ティーエムイーエム１６エー リミテッド | 呼吸器疾患を治療するためのベンゾイミダゾール誘導体 |
| WO2024151890A1 (en) * | 2023-01-11 | 2024-07-18 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858614B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenolic guanidine sodium channel blockers |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6903105B2 (en) | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| KR20060037450A (ko) | 2003-08-18 | 2006-05-03 | 패리온 사이언스 인코퍼레이티드 | 사이클릭 피라지노일구아니딘 나트륨 채널 차단제 |
| CA2534568A1 (en) | 2003-08-18 | 2005-03-24 | Parion Sciences, Inc. | Aliphatic pyrazinoylguanidine sodium channel blockers |
| US7064129B2 (en) | 2003-08-18 | 2006-06-20 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US20050090505A1 (en) | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US7399766B2 (en) | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| US7807834B2 (en) | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| GB0526240D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| WO2008124491A1 (en) | 2007-04-03 | 2008-10-16 | Parion Sciences, Inc. | Pyrazinoylguanidine compounds for use taste modulators |
| AU2008248598B2 (en) | 2007-05-07 | 2011-11-17 | Novartis Ag | Organic compounds |
| WO2009019506A1 (en) | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| PL2444120T3 (pl) | 2007-12-10 | 2018-02-28 | Novartis Ag | Spirocyklicze analogi amiloridu jako blokery ENac |
| BRPI0907823A2 (pt) | 2008-02-26 | 2015-07-21 | Parion Sciences Inc | Bloqueadores poliaromáticos dos canais de sódio |
| KR20110011621A (ko) | 2008-05-13 | 2011-02-08 | 노파르티스 아게 | ３，５―디아미노―６―클로로―피라진―２―카르복실산 유도체 및 기도 질환의 치료를 위한 상피 나트륨 채널 차단제로서의 이들의 용도 |
| KR20110040818A (ko) | 2008-06-10 | 2011-04-20 | 노파르티스 아게 | 상피 나트륨 채널 차단제로서의 피라진 유도체 |
| WO2011028740A1 (en) | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| AR086745A1 (es) * | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| PT2773633T (pt) | 2011-11-02 | 2017-11-14 | Boehringer Ingelheim Int | Compostos heterocíclicos, medicamentos contendo os referidos compostos, sua utilização e processos para a sua preparação |
| US8859559B2 (en) | 2011-12-20 | 2014-10-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
| EP3366680B1 (en) | 2012-05-29 | 2020-05-13 | Parion Sciences, Inc. | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases |
| US8841309B2 (en) | 2012-09-24 | 2014-09-23 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
| CN104995178B (zh) | 2012-12-17 | 2018-06-26 | 帕里昂科学公司 | 3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物 |
| RU2015129065A (ru) | 2012-12-17 | 2017-01-25 | Пэрион Сайенсиз, Инк. | Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов |
| ES2674665T3 (es) | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
| JP6353032B2 (ja) | 2013-04-30 | 2018-07-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジアミノピラジン化合物、前記化合物を含有する医薬、その使用、およびその調製方法 |
| JP2016525508A (ja) | 2013-07-02 | 2016-08-25 | ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ | 嚢胞性線維症の処置のための化合物 |
| EP3019492B1 (en) | 2013-07-08 | 2017-09-06 | Boehringer Ingelheim International GmbH | Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways |
| JP6461133B2 (ja) | 2013-07-15 | 2019-01-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規４置換及び５置換ベンゾイミダゾリウム化合物 |
| EP3022198B1 (en) | 2013-07-15 | 2019-09-11 | Boehringer Ingelheim International GmbH | Novel 5-substituted benzimidazolium compounds |
| JP6461134B2 (ja) | 2013-07-15 | 2019-01-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ベンゾイミダゾリウム化合物 |
| EP3030555B1 (en) | 2013-08-08 | 2019-01-30 | Boehringer Ingelheim International GmbH | Novel pyrazine amide compounds |
| US20180002312A1 (en) | 2015-01-12 | 2018-01-04 | Boehringer Ingelheim International Gmbh | Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| EP3245201B1 (en) | 2015-01-12 | 2019-06-19 | Boehringer Ingelheim International GmbH | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| EP3245199B1 (en) | 2015-01-12 | 2020-01-01 | Boehringer Ingelheim International GmbH | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| JP6847838B2 (ja) | 2015-01-12 | 2021-03-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 上皮ナトリウムチャネル阻害剤としての２−（ピラジン−２−イルカルボニルアミノメチル）ベンズイミダゾリウム化合物 |
| KR20180040699A (ko) | 2015-08-20 | 2018-04-20 | 베링거 인겔하임 인터내셔날 게엠베하 | 신규한 어닐링된 벤즈아미드 |
| WO2017028927A1 (en) | 2015-08-20 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Novel annelated phenoxyacetamides |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
-
2017
- 2017-10-17 GB GBGB1717051.5A patent/GB201717051D0/en not_active Ceased
-
2018
- 2018-10-17 JP JP2020521539A patent/JP7269923B2/ja active Active
- 2018-10-17 EP EP18795732.9A patent/EP3697788B1/en active Active
- 2018-10-17 WO PCT/GB2018/052983 patent/WO2019077340A1/en not_active Ceased
- 2018-10-17 US US16/756,416 patent/US11370778B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537658A5 (enExample) | ||
| JP2019535747A5 (enExample) | ||
| KR102827138B1 (ko) | 화합물 | |
| ES2292988T3 (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| JP2013530179A5 (enExample) | ||
| KR101738700B1 (ko) | β2 아드레날린성 수용체의 아고니스트로서의 5-（2-｛［6-（2,2-디플루오로-2-페닐에톡시）헥실］아미노｝-1-히드록시에틸）-8-히드록시퀴놀린-2（1Ｈ）-온의 메실레이트 염 | |
| JP2018199684A5 (enExample) | ||
| JP6392242B2 (ja) | 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体 | |
| JP7015286B2 (ja) | チオ糖粘液溶解薬 | |
| EA016203B1 (ru) | Производные амина | |
| JP2017535525A5 (enExample) | ||
| JP6666345B2 (ja) | 抗真菌化合物 | |
| BRPI0707559B1 (pt) | polimorfo de forma i do sal de ácido succínico de 1- [2- (2- cloro- 4- {[(r)- 2- hidróxi- 2- (8- hidróxi- 2- oxo- 1,2- diidroquinolin- 5- il) etilamino] meti1]}- 5- metoxifenilcarbamoil) etil] piperidin- 4- il éster de ácido bifenil- 2- il- carbâmico, seu processo de preparo e usos | |
| US9259376B2 (en) | Process for dry powder formulations | |
| JP2007505931A5 (enExample) | ||
| JPWO2019145726A5 (enExample) | ||
| WO2014159637A1 (en) | Methods of treating b2-bradykinin receptor mediated angioedema | |
| JP2007522141A (ja) | 呼吸器疾患の処置のためのベンゾチアゾール−２−オンベータ２アドレナリン受容体アゴニストとコルチコステロイドの組合せ剤 | |
| JP2013542267A5 (enExample) | ||
| JP6392243B2 (ja) | アリールアルキル及びアリールオキシアルキル置換の上皮ナトリウムチャネル遮断化合物 | |
| JP2024161441A (ja) | 呼吸器疾患の処理のための新規な化合物 | |
| BRPI0618524A2 (pt) | uso de diaril ureias para o tratamento de hipertensão pulmonar, bem como combinação e composição compreendendo as referidas diaril ureias e uso da combinação | |
| US20100093866A1 (en) | Pharmaceutical Formulations | |
| JP2023518356A (ja) | Ｃｏｖｉｄ－１９関連状態の治療のための方法 | |
| KR20200030107A (ko) | 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법 |